Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
ado-trastuzumab emtansine + pertuzumab
- Development stage
- Unknown
- Lead developer
- Genentech
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Administration
- Intravenous
01
Overview
A combination therapy consisting of ado-trastuzumab emtansine (T-DM1) and pertuzumab for the treatment of HER2-positive breast cancer. Ado-trastuzumab emtansine is an antibody-drug conjugate that combines the anti-HER2 antibody trastuzumab with the cytotoxic agent DM1 (a derivative of maytansine), while pertuzumab is a HER2-targeted monoclonal antibody that binds to a different site on the HER2 receptor, blocking HER2/HER3 heterodimerization. This combination leverages dual HER2-targeting mechanisms while delivering chemotherapy directly to tumor cells.
- Brand names
- Kadcyla + Perjeta
- Other names
- trastuzumab emtansine + pertuzumab
02
Targets
HER2 ECD subdomain II (Human epidermal growth factor receptor 2 dimerization interface)TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on ado-trastuzumab emtansine + pertuzumab.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on ado-trastuzumab emtansine + pertuzumab.